# Study to Assess Adverse Events and Compare How Oral Ubrogepant and Oral Atogepant Moves Through the Body of Healthy Female Adult Volunteers

> **NCT05892757** · PHASE1 · COMPLETED · sponsor: **AbbVie** · enrollment: 24 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Atogepant
- **DRUG:** Ubrogepant

## Key facts

- **NCT ID:** NCT05892757
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-11
- **Primary completion:** 2024-02-22
- **Final completion:** 2024-02-22
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05892757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05892757, "Study to Assess Adverse Events and Compare How Oral Ubrogepant and Oral Atogepant Moves Through the Body of Healthy Female Adult Volunteers". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT05892757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*